Biogen Idec is touting positive data from a mid-stage trial of an experimental A1 adenosine receptor antagonist therapy for heart failure. The study, published in the Journal of the American College of Cardiology, demonstrates that the drug has promise in preserving renal function for patients, a difficult condition to treat.
"Results showed that administration of oral Adentri for 10 days, in addition to standard heart failure therapy, was well tolerated and resulted in clinically significant increases in sodium excretion while preserving renal function," said Biogen Idec.
- see Biogen's release
- here's the AFX report